Mariam A Ahmed
Overview
Explore the profile of Mariam A Ahmed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhattacharya I, Rathmann S, Najdi S, Ahmed M, Heatherington A
Clin Pharmacol Ther
. 2025 Feb;
PMID: 39937057
No abstract available.
2.
Ahmed M, Krishna R, Rayad N, Albusaysi S, Mitra A, Shang E, et al.
Clin Pharmacol Ther
. 2024 Aug;
116(6):1412-1432.
PMID: 39148459
In the relentless pursuit of optimizing drug development, the intricate process of determining the ideal dosage unfolds. This involves "dose-finding" studies, crucial for providing insights into subsequent registration trials. However,...
3.
Mitra A, Tania N, Ahmed M, Rayad N, Krishna R, Albusaysi S, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(6):1398-1411.
PMID: 38989644
Model-informed approaches provide a quantitative framework to integrate all available nonclinical and clinical data, thus furnishing a totality of evidence approach to drug development and regulatory evaluation. Maximizing the use...
4.
Sanghavi K, Ribbing J, Rogers J, Ahmed M, Karlsson M, Holford N, et al.
CPT Pharmacometrics Syst Pharmacol
. 2024 Apr;
13(5):710-728.
PMID: 38566433
Modeling the relationships between covariates and pharmacometric model parameters is a central feature of pharmacometric analyses. The information obtained from covariate modeling may be used for dose selection, dose individualization,...
5.
Maurer M, Lumry W, Li H, Aygoren-Pursun E, Busse P, Jacobs J, et al.
J Allergy Clin Immunol Pract
. 2023 Sep;
12(1):201-211.e6.
PMID: 37730089
Background: Symptoms of hereditary angioedema (HAE) often first occur during childhood, and HAE attacks in children can be severe and substantially affect health-related quality of life (HRQoL). However, there are...
6.
Mitra A, Ahmed M, Krishna R, Sun K, Gibbons F, Campagne O, et al.
Clin Pharmacol Ther
. 2023 Jun;
114(3):515-529.
PMID: 37313953
The promise of viral vector-based gene therapy (GT) as a transformative paradigm for treating severely debilitating and life-threatening diseases is slowly coming to fruition with the recent approval of several...
7.
Ahmed M, Burnham J, Dwivedi G, Abuasal B
J Pharmacokinet Pharmacodyn
. 2023 May;
50(6):429-444.
PMID: 37140724
Pediatric populations represent a major fraction of rare diseases and compound the intrinsic challenges of pediatric drug development and drug development for rare diseases. The intertwined complexities of pediatric and...
8.
Bhattacharya I, Ahmed M
J Clin Pharmacol
. 2022 Dec;
62 Suppl 2:S6-S11.
PMID: 36461741
No abstract available.
9.
Abuasal B, Ahmed M, Patel P, Albusaysi S, Sabarinath S, Uppoor R, et al.
Clin Pharmacol Ther
. 2021 Dec;
111(4):786-798.
PMID: 34860361
Several challenges are associated with rare disease drug development in neurology. In this article, we summarize the US Food and Drug Administration's experience with clinical drug development for rare neurological...
10.
Ahmed M, Kalaria S, Younis I
J Clin Pharmacol
. 2021 May;
61(10):1324-1333.
PMID: 33997992
This analysis compared the results from noncompartmental analysis and population pharmacokinetic (PopPK) predictions of exposure changes in patients with renal impairment (RI) for 27 new molecular entities (NMEs) approved between...